Kim A Reiss (Reiss Binder), MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-360-0735
Fax: 215-662-4646
Fax: 215-662-4646
Education:
BA (Psychology)
Colby College, 2002.
Post BA (Pre-Med)
Johns Hopkins University , 2003.
MD (Medicine)
Penn State College of Medicine , 2008.
Permanent linkBA (Psychology)
Colby College, 2002.
Post BA (Pre-Med)
Johns Hopkins University , 2003.
MD (Medicine)
Penn State College of Medicine , 2008.
Selected Publications
Hannah J. Glover, Farahnaz Islam, Stephanie Thiede, Seung Won Hyun, Riccardo Miotto, Samuel Heilbroner, Zachary Rivers, Victoria L. Chiou, Timothy J. Taxter, Michelle M. Stein, Chani Stossel, Kim A. Reiss, Chithra Sangli, Charles T. Koyias, Halla Nimeiri, Diane M. Simeone, Talia Golan: AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer. ASCO Annual Meeting, Chicago, IL June 2026.Sean O'Connor, Nicholas Seewald, William J. Chapin. Abigail Doucette, Catherine Blaha, Kim A. Reiss: Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study. ASCO Annual Meeting, Chicago, IL June 2026.
*Vincent Chung, Katherine A. Guthrie, Michael Jon Pishvaian, Andrew Lowy, Davendra Sohal, Sarah Colby, Kim A. Reiss, Gazala Khan, Rafael Winograd, Jeffrey Meyerhardt, Eileen O'Reilly, E. Gabriela Chiorean, Philip Philip : SWOG2001: Olaparib Plus Pembrolizumab Versus Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer With Germline BRCA1/2 Mutations. Rapid Oral Abstract Session, ASCO 2026, Chicago, IL June 2026.
Maheswari Senthil, Sung C. Hong, Nataliya V. Uboha, Farshid Dayyani, Xin Yao, Mehraneh D. Jafari, Ibrahim Nassour, Kim A. Reiss, Shishir K. Maithel, Jordan Berlin: A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234. ASCO Annual Meeting, Chicago, IL June 2026.
William J. Chapin, Nadia Cenou, Devora Delman, Jennifer R. Eads, Michele Manley, Kim A. Reiss, Megan Sackey, Ursina R. Teitelbaum, Jennifer Walsh, Gregory L. Beatty, Mark H. O'Hara: Phase II trial of pembrolizumab in combination with odetiglucan for patients with metastatic colorectal adenocarcinoma with liver-predominant disease. ASCO Annual Meeting, Chicago, IL June 2026.
Kim A. Reiss, Mingyi Xia, Mwangala Akamandisa, Kurt D’Andrea, Brad Wubbenhorst, Christopher J. Lord, Stephen J. Pettitt, Andrew N.J. Tutt, Ch.B., Ph.D5, Timothy J. Brown, MD, Mark H. O’Hara, MD, Charles Schneider, Ursina Teitelbaum, Zain Hannan, Ryan Hood, Rashmi Tondon, Robert H Vonderheide, MD, DPhil, Susan M. Domchek, MD, and Katherine L. Nathanson, MD: Long-Term Outcomes of BRCA+ or PALB2+ Pancreatic Cancer Patients Treated with Maintenance Rucaparib. JAMA Oncology Apr 2026 Notes: in press.
Alison M. Schram, Olumide B. Gbolahan, Cindy Neuzillet, Dirk Arnold, Antoine Hollebecque, Richard Greil, Mohammed Najeeb Al Hallak Jordi Rodon Ahnert, Kim A. Reiss, Paul F. La Porte, Tormod Kyrre Guren, Carolyn E. Ragsdale, Fiona Garner, Alejandro D. Ricart, Shola Adeyemi,13 Christoph Springfeld : Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: analysis from the phase 2 eNRGy trial. ASCO GI 2026, San Francisco, CA Jan 2026.
Alison M. Schram, Olumide B. Gbolahan, Cindy Neuzillet, Dirk Arnold, Antoine Hollebecque, Richard Greil, Mohammed N. Al Hallak, Jordi Rodon Ahnert, Kim A. Reiss, Paul La Porte, Tormod Kyrre Guren, Carolyn E. Ragsdale, Fiona Garner, Alejandro D. Ricart, Shola Adeyemi, Christoph Springfeld: Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial. ASCO GI, San Francisco, CA Jan 2026.
John C McVey, Max M Wattenberg, Heather Coho, Kayjana Infante, Kelly Markowitz, Devora Delman, Cynthia Clendenin, Emma E Furth, Rashmi Tondon, Ben Z Stanger, Robert H Vonderheide, Kim A Reiss, Gregory L Beatty: Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. Scientific Reports Jan 2026.
Ben Boursi, MD; Zakary L. Kolkey, MD; Kim Anna Reiss, MD; Mark H. O’Hara, MD; William Chapin, MD, MSCE : Comparative effectiveness of oxaliplatin or irinotecan rechallenge/reintroduction vs standard third-line therapies in patients with metastatic colorectal cancer. ASCO GI 2026, San Francisco, CA Jan 2026.